Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Henlius HLX01 (Rituximab Injection) Wins "Biosimilar Initiative of the Year" at Global Generics & Biosimilars Awards 2019

PR Newswire Asia Wednesday, 6 November 2019 ()
SHANGHAI, Nov. 7, 2019 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), a leading biopharmaceutical company in China focusing on oncology and autoimmune diseases, won the award of "Biosimilar Initiative of the Year" (HLX01, rituximab injection) and was also shortlisted for the award of "the Company of the Year, Asia-Pacific" at the 6^th Global Generics & Biosimilars Awards 2019 ceremony held on 5 November 2019 in Frankfurt, Germany, which makes Henlius the first Chinese enterprise to clinch the award.

The award was organized by Generics Bulletin, a world-renowned trade magazine in UK and co-hosted by IQVIA, a leading global provider of information and innovative technology solutions for healthcare clients. Henlius stood out from hundreds of enterprises over the past two months, during which the committee comprising about 20 expert judges invited from the generics and biosimilars industries engaged in the judging process independently. The recognition by "Global Generics & Biosimilars Awards 2019" not only highlights Henlius' impressive performance in the biotech industry, but also recognizes the company's influence in Asia-Pacific, and even in the global biopharmaceutical markets.

In 2019, Henlius has achieved significant breakthrough in biosimilar field. Its first product HLX01 was granted New Drug Application (NDA) approval by the National Medical Products Administration (NMPA) in February for all the indications of originator approved in China, making it the first biosimilar in China. Its first prescription was issued on May 16, making HLX01 the first China-developed biosimilar benefiting patients. Moreover, it fills the market gap for biosimilars in China and improves the patients' access to high quality biological medicine. Over 1000 patients were benefited in the first month after the commercial launch of HLX01.

*About Henlius*

Founded in 2010 and headquartered in Shanghai, Henlius (2696.HK) is committed to biosimilar, innovative monoclonal antibody (mAb) products and immuno-oncology combination therapies with proprietary anti-PD-1/PD-L1 mAbs as backbone, and builds an integrated platform covering the entire product lifecycle from R&D, commercial-scale production to commercialization.

As of today, two candidates are under New Drug Application (NDA) priority review in China and one candidate is under Marketing Authorisation Application (MAA) review in Europe. In addition to one product launched commercially, Henlius has conducted over 30 clinical studies for 14 products and 6 combination therapies worldwide.
0
shares
ShareTweetSavePostSend
 

Recent related news from verified sources

Global PEO Services Wins Silver Stevie® Award in 2019 International Business Awards®

Global PEO Services Wins Silver Stevie® Award in 2019 International Business Awards®
SALT LAKE CITY--(BUSINESS WIRE)--Global PEO Services has won HR Team of the Year at the International Business Stevie Awards.
Business Wire Also reported by •E! OnlineNewsVoir

Jennifer Aniston Pays Tribute to 'Friends' While Accepting Icon Award at People's Choice Awards 2019 - Watch Now!

Jennifer Aniston is the 2019 People’s Icon! The 50-year-old actress was honored by Adam Sandler with the prestigious award at the 2019 E! People’s Choice...
Just Jared Also reported by •E! OnlineJust Jared Jr

You Might Like


Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.